New Knee Treatments 2025-2026: What’s Proven, What’s Promising, and What’s Available Now

If you’re living with chronic knee pain from osteoarthritis, 2025 and 2026 bring both exciting innovations and proven solutions that can help you avoid surgery. With knee osteoarthritis affecting approximately 528 million people worldwide—including 23% of the global population aged 40 and older—the demand for effective non-surgical treatments has never been greater [1].

The good news? While researchers continue developing cutting-edge therapies, several highly effective treatments are already available and covered by insurance, including Medicare. Whether you’re exploring options for the first time or reconsidering treatments you’ve heard about, understanding what’s proven versus what’s still experimental can help you make the best decision for your knee pain.

Understanding Knee Osteoarthritis: The Growing Challenge

Osteoarthritis affects the knee joint more than any other location, representing 60-85% of all OA cases [1]. The lifetime risk of developing symptomatic knee osteoarthritis is approximately 45%, affecting 40% of men and 47% of women [1]. As we age, the risk increases significantly—affecting 33.6% of adults aged 65 and older.

The impact extends beyond discomfort. Knee osteoarthritis costs approximately $65 billion annually in direct healthcare costs in the United States alone [1]. More importantly, it affects quality of life, limiting mobility, independence, and daily activities.

The Evolution of Non-Surgical Knee Treatment

Non-surgical treatment remains the cornerstone of care for knee osteoarthritis. Evidence consistently supports core interventions including patient education, self-management, weight reduction, and structured exercise [1]. However, when conservative measures aren’t enough, advanced interventional treatments offer hope for pain relief without surgery.

Let’s explore what’s new, what’s proven, and what you should know about knee treatment options in 2025-2026.

Viscosupplementation: The Proven Standard That’s Still Leading

What Is Viscosupplementation?

Viscosupplementation involves injecting hyaluronic acid (HA) gel directly into the knee joint to replace depleted synovial fluid. This treatment helps restore the natural cushioning and lubrication in arthritic knees, reducing pain and improving function [2].

Latest Evidence on Effectiveness

While some controversy exists in the medical literature, clinical evidence shows that viscosupplementation provides meaningful relief for many patients, particularly those with mild to moderate osteoarthritis [2]. Studies demonstrate that relief can start as early as 2-4 weeks, usually peaks between 4-12 weeks, and may last up to 6 months or longer [2].

The key to success often lies in proper patient selection and injection technique—which is where precision matters most.

High-Molecular-Weight Formulations: The New Generation

Recent innovations have led to high-molecular-weight hyaluronic acid (HMWHA) formulations that show superior effectiveness compared to older products. Research demonstrates that HMWHA provides more significant pain relief than both non-selective NSAIDs and selective COX-2 inhibitors [3].

The Precision Advantage: Fluoroscopy-Guided Injections

One of the most significant advances in viscosupplementation isn’t a new drug—it’s improved delivery. Research confirms that fluoroscopy-guided injections dramatically improve accuracy compared to “blind” injections. Studies show that non-guided injections miss the joint up to 30% of the time [4].

Fluoroscopy provides real-time X-ray imaging during injection, allowing physicians to:

• Visualize exact needle placement
• Confirm medication reaches the correct location
• Avoid common pitfalls like inadvertent fat pad injection
• Ensure optimal distribution throughout the joint space

Patients who receive fluoroscopy-guided injections experience significantly better pain relief and improved joint function compared to traditional blind injections [4].

Insurance Coverage for Viscosupplementation

Medicare covers viscosupplementation when deemed medically necessary, typically requiring documentation of symptomatic osteoarthritis with radiographic evidence and at least three months of unsuccessful conservative treatment [5]. Medicare Part B covers 80% of approved costs after the deductible, with patients responsible for the remaining 20% [5].

Most private insurance plans also provide coverage for viscosupplementation, making it an accessible option for many patients.

PRP (Platelet-Rich Plasma): Refined and Increasingly Effective

What’s New in PRP for 2025

Platelet-rich plasma therapy has evolved significantly, with 2025 research providing clearer guidance on when and how PRP works best. A comprehensive review of 40 high-quality studies published between 2013 and March 2025 reveals important advances [6].

The Concentration Connection

One of the most important discoveries: platelet concentration matters significantly. High-platelet PRP provides superior pain relief and more durable functional improvement compared to low-platelet formulations. The benefits of high-platelet PRP extend to the 12-month follow-up, while low-platelet PRP shows diminishing returns [6].

Clinical Effectiveness

Recent meta-analyses demonstrate that PRP produces statistically and clinically superior improvement compared to placebo at all follow-up points, with improvements exceeding the 6.4 minimal clinically important difference (MCID) [6]. Leukocyte-poor PRP shows particularly strong results, especially for patients with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades I-III) [6].

PRP vs. Viscosupplementation

Studies comparing PRP with hyaluronic acid show that PRP—particularly leukocyte-poor PRP—demonstrates superior pain relief and functional improvement, with sustained benefits lasting 12-24 months [6].

Optimal Patient Selection

PRP is most commonly offered to relatively young or active patients aged 40-65 years with preserved joint space. While older patients may consider PRP, those with advanced bone-on-bone arthritis may experience limited benefit [6].

Safety and Accessibility

PRP appears safe with few adverse events reported. However, it remains costly and variably reimbursed by insurance [6]. Sequential PRP treatments—typically 2-3 treatments spaced 4-6 weeks apart—can yield results comparable to stem cell therapy at a lower cost [7].

Genicular Artery Embolization (GAE): The Minimally Invasive Innovation

What Is GAE?

Genicular artery embolization represents one of the most innovative non-surgical treatments emerging for knee osteoarthritis. This minimally invasive procedure targets the tiny blood vessels that supply inflamed synovial tissue in the knee joint [8].

How GAE Works

Chronic knee pain from osteoarthritis often results from inflammation in the synovial lining. This inflammation leads to increased blood vessel formation (neovascularization). GAE works by reducing perfusion to these abnormal blood vessels, thereby diminishing synovial inflammation and pain [8].

2025 Clinical Evidence

Recent 2025 data from prospective trials published in the Journal of Vascular and Interventional Radiology demonstrates that GAE is a safe treatment providing clinically significant pain relief for a subset of patients [8]. Notably, the procedure shows reductions in serum VEGF and IL-1Ra levels—biomarkers associated with inflammation—which may contribute to both local pain relief and decreased joint inflammation [8].

Long-Term Outcomes

Two-year follow-up data reveals that 72% of patients who initially responded to GAE maintained durable results at 24 months, though 28% experienced relapsed symptoms [8]. Overall, 47% of all treated patients demonstrated clinical success at 24 months [8].

Who’s a Good Candidate?

Current evidence supports GAE for patients with mild-to-moderate osteoarthritis who experience persistent symptoms despite conservative treatments such as physical therapy, weight management, or intra-articular injections [8]. The procedure is suitable for a broad patient population, including people from 40 to 80 years old, athletes, and individuals with persistent pain after knee replacement [8].

Safety Profile

No long-term adverse events were observed after GAE, with predominantly mild and transient side effects [8].

Current Availability

GAE is performed by interventional radiologists at specialized medical centers. While still considered relatively new, availability is expanding as more centers adopt the technique.

COOLIEF Cooled Radiofrequency Ablation: FDA-Cleared for OA Pain

What Is COOLIEF?

COOLIEF represents the first FDA-cleared radiofrequency treatment specifically for moderate to severe osteoarthritis of the knee [9]. This procedure uses water-cooled radiofrequency ablation to deactivate the genicular nerves responsible for sending pain signals to the brain.

The Cooling Advantage

Traditional radiofrequency ablation can cause tissue overheating, limiting the treatment area. COOLIEF’s water-cooling technology prevents overheating, allowing treatment of a larger area and making it significantly more effective [9].

Clinical Outcomes

Research demonstrates impressive results:

• Duration of greater than 50% pain reduction: 11.1 months for cooled RFA compared to just 2.6 months for traditional radiofrequency [9]
• Sustained pain relief and functional improvement up to 24 months after a single application [9]
• Superior results compared to intra-articular steroid injections in terms of pain relief, physical function, and patient satisfaction [9]

How COOLIEF Compares

When compared head-to-head with a single hyaluronic acid injection, COOLIEF demonstrated significantly greater and longer-lasting pain relief [9]. The procedure is minimally invasive, non-opioid, and targets the pain at its source—the nerves surrounding the knee joint.

Is COOLIEF Right for You?

COOLIEF is particularly valuable for patients with moderate to severe osteoarthritis who haven’t found adequate relief from injections or want longer-lasting results without repeated treatments.

Stem Cell Therapy: Promising but Still Evolving

The Current Landscape

Stem cell therapy for knee osteoarthritis continues to generate significant research interest. A global analysis identified 224 clinical trials worldwide, with the number steadily increasing [7]. China leads in trials, followed by the United States and South Korea [7].

What the Latest Evidence Shows

A Cochrane review published in April 2025 provides a cautious assessment: stem cell injections for knee osteoarthritis may slightly improve pain and function compared to placebo injections, though the evidence remains low-certainty [7]. Serious adverse events were infrequently reported, though all invasive joint procedures carry a small risk [7].

Mesenchymal Stem Cells (MSCs)

Most trials focus on mesenchymal stem cells, with adipose-derived MSCs (28.4%) and umbilical cord-derived MSCs (26.2%) being the most common sources [7].

A Novel Development: The “Pain Sponge”

One of the most intriguing developments announced in December 2025 involves SereNeuro Therapeutics’ SN101, a first-in-class iPSC-derived therapy. This treatment uses lab-grown nociceptors that act like sponges, absorbing inflammatory pain factors without sending pain signals to the brain [7]. While still in research phases, this represents an innovative approach to both pain relief and joint protection.

The Bottom Line on Stem Cells

While stem cell therapy shows promise, it remains largely experimental with variable results. Sequential PRP treatments often achieve comparable results at lower cost and with more established protocols [7]. For patients interested in stem cell therapy, participation in clinical trials at reputable institutions may be the best option.

Arthrosamid: The Long-Lasting Hydrogel (Not Yet in the US)

What Makes Arthrosamid Different?

Arthrosamid is an injectable polyacrylamide hydrogel that differs fundamentally from traditional hyaluronic acid injections. Rather than being gradually absorbed, Arthrosamid integrates into the synovial tissue, providing structural support and cushioning with a single injection [10].

Impressive Clinical Data

The LUNA Study involving 199 participants showed significant reduction in WOMAC pain scores from baseline to 52 weeks, with monitoring planned for up to five years [10]. Patient reports suggest pain relief lasting up to four years—far longer than traditional viscosupplementation [10].

2025 Developments

New data presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in April 2025 included 10-year follow-up safety data and 5-year efficacy results [11]. More than 20,000 patients have been treated across 400+ clinics in Europe, Canada, and New Zealand [10].

US Availability

Arthrosamid is not yet FDA-approved in the United States, though it gained approval in Canada in early 2025 with the first North American injection performed in March 2025 [10]. Patients interested in this treatment may need to monitor FDA approval status or travel internationally.

The Combination Approach: Hyaluronic Acid Plus PRP

Synergistic Benefits

Emerging evidence suggests that combining hyaluronic acid with platelet-rich plasma may offer synergistic benefits by enhancing both the biological and mechanical properties of joints [3]. Research published in 2025 examined the clinical efficacy of these combination approaches, showing promise for patients who want to maximize results.

Who Benefits Most?

Combination therapy may be particularly valuable for patients with moderate osteoarthritis who haven’t achieved adequate relief from single-agent treatment.

What About Surgery? When Is Knee Replacement Necessary?

While this article focuses on non-surgical options, it’s important to acknowledge that some patients ultimately benefit from knee replacement surgery. Surgery typically becomes appropriate when:

• Conservative and advanced non-surgical treatments have failed
• Pain significantly limits daily activities and quality of life
• Structural damage is severe (bone-on-bone arthritis)
• Patients are medically suitable surgical candidates

The good news: many patients who pursue non-surgical treatments can delay or avoid surgery altogether, maintaining good function and quality of life.

Making the Right Choice: Questions to Ask Your Doctor

When considering knee treatment options, discuss these questions with your physician:

1. Based on my specific condition, which treatments am I a good candidate for?
2. What is your experience with fluoroscopy-guided injections?
3. Should I try viscosupplementation first, or is a different approach better for my situation?
4. How do you determine platelet concentration for PRP treatments?
5. Are you familiar with newer options like GAE or COOLIEF?
6. Does my insurance cover these treatments?
7. What results can I realistically expect?
8. How long do results typically last, and what happens if the first treatment doesn’t work?

The Joint Relief Institute Approach: Precision-Guided Treatment

At Joint Relief Institute, we’ve performed over 400,000 procedures for more than 40,000 patients, earning a 4.9 Google rating. Our approach emphasizes precision and proven results:

Fluoroscopy-Guided Viscosupplementation

We use fluoroscopy guidance for all knee injections, ensuring accurate medication delivery and optimal outcomes. This technology-enhanced approach addresses one of the most common reasons for treatment failure—inaccurate injection placement.

Comprehensive Evaluation

Dr. Michael Hana and our team perform thorough evaluations to determine which treatment approach offers the best chance of success for your specific condition. We consider factors including:

• Severity of osteoarthritis (imaging findings)
• Previous treatments and results
• Activity level and functional goals
• Medical history and contraindications
• Insurance coverage and cost considerations

Medicare and Insurance Accepted

We accept Medicare and most major insurance plans, making proven non-surgical treatment accessible when you need it.

The Future: What’s on the Horizon for 2026 and Beyond

Research continues advancing on multiple fronts:

• Topical hyaluronic acid formulations offering non-invasive delivery methods [3]
• Extended-release formulations addressing the fast clearance that limits current HA effectiveness [3]
• Regenerative medicine approaches targeting cartilage repair at the cellular level
• Master regulators of aging: Stanford researchers recently identified approaches to regenerate joint cartilage by inhibiting aging pathways [1]
• Personalized medicine: Using biomarkers and imaging to predict which patients will respond best to specific treatments

Take Action: Don’t Let Knee Pain Control Your Life

If you’re struggling with chronic knee pain, you don’t have to accept it as an inevitable part of aging. Multiple effective, non-surgical treatment options exist right now—and they’re covered by insurance.

The key is working with experienced specialists who use proven techniques, proper imaging guidance, and comprehensive approaches tailored to your specific needs.

Contact Joint Relief Institute Today

Call (800) 238-9307 to schedule a consultation with Dr. Michael Hana and discover which knee treatment option is right for you.

With decades of experience, cutting-edge technology, and a patient-first approach, Joint Relief Institute has helped tens of thousands of patients find relief from chronic knee pain. Let us help you get back to the activities you love—without surgery.

Key Takeaways: New Knee Treatments 2025-2026

• Viscosupplementation remains highly effective, especially with fluoroscopy-guided precision and high-molecular-weight formulations
• PRP therapy has evolved, with high-platelet, leukocyte-poor formulations showing excellent results for properly selected patients
• Genicular artery embolization (GAE) offers a novel approach with promising 2-year outcomes and excellent safety
• COOLIEF radiofrequency ablation is FDA-cleared for knee OA, providing up to 24 months of relief
• Stem cell therapy shows promise but remains experimental with variable results
• Combination approaches (HA + PRP) may offer enhanced benefits
• Arthrosamid hydrogel demonstrates 4-year pain relief in international markets (not yet US-approved)
• Insurance coverage, including Medicare, makes proven treatments accessible now

The future of knee treatment is bright, but you don’t have to wait. Proven, effective options are available today.

Frequently Asked Questions

What is the newest treatment for knee pain in 2025?

The newest FDA-cleared treatment is COOLIEF cooled radiofrequency ablation, which provides up to 24 months of pain relief by targeting the genicular nerves. Additionally, genicular artery embolization (GAE) has emerged as an innovative minimally invasive option with promising clinical results.

Are knee gel injections still effective?

Yes, viscosupplementation (knee gel injections) remains effective, particularly when delivered with fluoroscopy guidance and using high-molecular-weight hyaluronic acid formulations. Studies show relief lasting 6 months or longer for properly selected patients with mild to moderate osteoarthritis.

Does Medicare cover new knee treatments?

Medicare covers viscosupplementation when medically necessary, typically paying 80% of approved costs after the deductible. Coverage for newer treatments like GAE and COOLIEF varies by region and medical policy. Contact your provider or Medicare contractor for specific coverage information.

How does PRP compare to stem cell therapy for knees?

Recent research suggests that sequential PRP treatments—typically 2-3 sessions spaced 4-6 weeks apart—can achieve results comparable to stem cell therapy. PRP has more established protocols, better evidence, and generally lower costs, while stem cell therapy remains largely experimental.

What’s the difference between traditional and fluoroscopy-guided knee injections?

Fluoroscopy uses real-time X-ray imaging to guide needle placement, ensuring medication reaches the correct location in the joint. Research shows non-guided injections miss the joint up to 30% of the time, while fluoroscopy-guided injections dramatically improve accuracy and clinical outcomes.

How long do different knee treatments last?

Treatment duration varies: viscosupplementation typically lasts 6 months, high-quality PRP 12-24 months, COOLIEF radiofrequency ablation up to 24 months, GAE shows 72% maintaining relief at 2 years among responders, and Arthrosamid (international markets) up to 4 years.

Can I avoid knee replacement surgery with these treatments?

Many patients successfully delay or avoid knee replacement using non-surgical treatments. Success depends on osteoarthritis severity, treatment selection, and individual response. Patients with mild to moderate OA have the highest success rates with non-surgical approaches.

Are these new knee treatments safe?

Current evidence shows excellent safety profiles for most treatments. Viscosupplementation, PRP, GAE, and COOLIEF all demonstrate predominantly mild and transient side effects with no significant long-term adverse events in clinical studies.

Sources

1. Frontiers in Medicine. “Recent advances in the management of knee osteoarthritis: a narrative review.” January 2025. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1523027/full

2. Cleveland Clinic. “Knee Gel Injections (Viscosupplementation): Uses & Side Effects.” https://my.clevelandclinic.org/health/procedures/knee-gel-injections-viscosupplementation

3. MDPI - Journal of Clinical Medicine. “Intra-Articular Hyaluronic Acid for Knee Osteoarthritis: A Systematic Umbrella Review.” 2025. https://www.mdpi.com/2077-0383/14/4/1272

4. Joint Relief Institute. “Fluoroscopy-Guided Injections Add Precision in Hyaluronic Acid Shots.” https://jointreliefinstitute.com/blog/enhancing-precision-in-hyaluronic-acid-injections-the-effectiveness-of-fluoroscopy/

5. The Modern Medicare Agency. “Does Medicare Cover Gel Knee Injections?” 2025. https://www.paulbinsurance.com/does-medicare-cover-gel-knee-injections-insights-from-the-modern-medicare-agency/

6. MDPI - Journal of Clinical Medicine. “Platelet-Rich Plasma for Knee Osteoarthritis: A Comprehensive Narrative Review.” May 2025. https://www.mdpi.com/2077-0383/14/11/3983

7. Frontiers in Cell and Developmental Biology. “Global Clinical Trial Landscape of Stem Cell-Based Therapies for Osteoarthritis.” January 2026. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2026.1757935/abstract

8. Journal of Vascular and Interventional Radiology. “A Prospective Single-Arm Trial of Genicular Artery Embolization for Symptomatic Knee Osteoarthritis.” 2025. https://www.jvir.org/article/S1051-0443(25)00529-9/fulltext

9. COOLIEF. “About COOLIEF Cooled Radiofrequency ablation for chronic knee pain.” https://www.mycoolief.com/about/

10. Arthrosamid. “Patient access to innovative procedure for treating knee osteoarthritis set to grow in 2025.” https://arthrosamid.com/en-CA/post/patient-access-to-innovative-procedure-for-treating-knee-osteoarthritis-set-to-grow-in-2025-as-the-pure-sport-medicine-group-partners-with-contura-orthopaedics

11. Arthrosamid. “New 10-year data on Arthrosamid safety profile & 5-year data on long term efficacy to Be Presented at WCO 2025.” https://arthrosamid.com/post/new-10-year-data-on-arthrosamid-safety-profile-5-year-data-on-long-term-efficacy-to-be-presented-for-the-first-time-at-wco-2025-10-13-april

12. University of Miami Health. “Genicular Artery Embolization: A Minimally Invasive Approach to Knee Osteoarthritis.” https://news.med.miami.edu/genicular-artery-embolization-a-minimally-invasive-approach-to-knee-osteoarthritis/